Clinical Trial Detail

NCT ID NCT02428855
Title Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Massachusetts General Hospital
Indications

intrahepatic cholangiocarcinoma

Therapies

Dasatinib

Age Groups: adult

Additional content available in CKB BOOST